A sub-analysis of the ROCKET-AF trial showed that patients with atrial fibrillation who took the new anticoagulant rivaroxaban to prevent stroke were 40% less likely to have intracranial hemorrhages than warfarin users. Researchers also found that adding clopidogrel to either warfarin or rivaroxaban increased the risk of intracranial bleeding by 250% compared with clopidogrel or warfarin alone.

Related Summaries